Aescap portfolio company Ionis announced today that its medicine candidate Olezarsen has shown a statistically significant reduction in triglyceride levels in a phase 3 clinical study.
Aescap portfolio company Ionis announced today that its medicine candidate Olezarsen has shown a statistically significant reduction in triglyceride levels in a phase 3 clinical study.